Endocrine Therapy-related Endocrinopathies—Biology, Prevalence, and Implications for the Management of Breast Cancer

Brown, Kristy A.; Andreopoulou, Eleni; Andreopoulou, Panagiota

doi:10.17925/ohr.2020.16.1.17

Cited by 4 publications

(3 citation statements)

References 108 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several BC patients demonstrate inherent drug resistance, while others are initially drug-sensitive but develop resistance to anticancer treatments and commonly display multidrug resistance, which may cause recurrence and/or metastasis even though the prognosis for BC patients has significantly improved [86][87][88]. Nowadays, medication resistance is a significant factor in poor prognosis, lowering BC patients' survival rates [89].…”

Section: B7-h3 and Breast Cancer Drug Resistancementioning

confidence: 99%

A promising target for breast cancer: B7-H3

Jiang,

Liu,

Chen

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Breast cancer (BC) is the second-leading factor of mortality for women globally and is brought on by a variety of genetic and environmental causes. The conventional treatments for this disease have limitations, making it difficult to improve the lifespan of breast cancer patients. As a result, extensive research has been conducted over the past decade to find innovative solutions to these challenges. Targeting of the antitumor immune response through the immunomodulatory checkpoint protein B7 family has revolutionized cancer treatment and led to intermittent patient responses. B7-H3 has recently received attention because of its significant demodulation and its immunomodulatory effects in many cancers. Uncontrolled B7-H3 expression and a bad outlook are strongly associated, according to a substantial body of cancer research. Numerous studies have shown that BC has significant B7-H3 expression, and B7-H3 induces an immune evasion phenotype, consequently enhancing the survival, proliferation, metastasis, and drug resistance of BC cells. Thus, an innovative target for immunotherapy against BC may be the B7-H3 checkpoint.In this review, we discuss the structure and regulation of B7-H3 and its double costimulatory/coinhibitory function within the framework of cancer and normal physiology. Then we expound the malignant behavior of B7-H3 in BC and its role in the tumor microenvironment (TME) and finally focus on targeted drugs against B7-H3 that have opened new therapeutic opportunities in BC.

show abstract

Section: B7-h3 and Breast Cancer Drug Resistancementioning

confidence: 99%

A promising target for breast cancer: B7-H3

Jiang,

Liu,

Chen

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…These cancers seriously endanger women’s physical and mental health. Treatment methods for the cancers mentioned above generally include radical surgical resection, radiotherapy, and chemotherapy ( Brown et al, 2020 ; Butala et al, 2021 ; Rütten et al, 2021 ). Although the treatments as mentioned earlier can significantly prolong the survival of patients, the overall prognosis is still unsatisfactory.…”

Section: Introductionmentioning

confidence: 99%

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies

Wang

Yan²,

Da³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Breast cancer and gynecological tumors seriously endanger women’s physical and mental health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and radiotherapy, the prognosis and overall survival of cancer patients have improved compared to earlier, but the management of advanced disease still faces great challenges. Recently, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been clinically approved for breast and gynecological cancer patients, significantly improving their quality of life, especially of patients with BRCA1/2 mutations. However, drug resistance faced by PARPi therapy has hindered its clinical promotion. Therefore, developing new drug strategies to resensitize cancers affecting women to PARPi therapy is the direction of our future research. Currently, the effects of PARPi in combination with other drugs to overcome drug resistance are being studied. In this article, we review the mechanisms of PARPi resistance and summarize the current combination of clinical trials that can improve its resistance, with a view to identify the best clinical treatment to save the lives of patients.

show abstract

“…Recently, immunotherapy and targeted therapies have altered the prognoses of patients with BC, improving their life quality and survival ( 2 ), ( 3 ). Despite significant improvement in the outcomes of BC patients, many of them present intrinsic drug resistance, while others are initially drug-sensitive but acquire resistance to anticancer drugs, and frequently multidrug resistance, leading to recurrence and/or metastasis ( 4 – 6 ). Furthermore, growing evidence revealed that patients with the same BC molecular subtype can have different responses to treatment, strongly supporting the high BC heterogeneity.…”

mentioning

confidence: 99%